Raras
Buscar doenças, sintomas, genes...
Histiocitose de células de Langerhans
ORPHA:389CID-10 · C96.0CID-11 · 2B31.2OMIM 604856DOENÇA RARA

A histiocitose de células de Langerhans (HCL) é uma doença sistêmica associada à proliferação e acúmulo (geralmente em granulomas) de células de Langerhans em vários tecidos.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A histiocitose de células de Langerhans (HCL) é uma doença sistêmica associada à proliferação e acúmulo (geralmente em granulomas) de células de Langerhans em vários tecidos.

Pesquisas ativas
36 ensaios
86 total registrados no ClinicalTrials.gov
Publicações científicas
5.886 artigos
Último publicado: 2026 Apr 1

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 100 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
1.5
Europe
Início
All ages
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: C96.0
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🫁
Pulmão
6 sintomas
🫃
Digestivo
5 sintomas
📏
Crescimento
4 sintomas
🧠
Neurológico
4 sintomas
🩸
Sangue
4 sintomas
🦴
Ossos e articulações
3 sintomas

+ 10 sintomas em outras categorias

Características mais comuns

90%prev.
Osteólise
Muito frequente (99-80%)
90%prev.
Dor óssea
Muito frequente (99-80%)
55%prev.
Febre
Frequente (79-30%)
55%prev.
Linfadenopatia
Frequente (79-30%)
55%prev.
Esplenomegalia
Frequente (79-30%)
55%prev.
Tosse
Frequente (79-30%)
40sintomas
Muito frequente (2)
Frequente (7)
Ocasional (15)
Muito raro (3)
Sem dados (13)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 40 características clínicas mais associadas, ordenadas por frequência.

OsteóliseOsteolysis
Muito frequente (99-80%)90%
Dor ósseaBone pain
Muito frequente (99-80%)90%
FebreFever
Frequente (79-30%)55%
LinfadenopatiaLymphadenopathy
Frequente (79-30%)55%
EsplenomegaliaSplenomegaly
Frequente (79-30%)55%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico5.886PubMed
Últimos 10 anos200publicações
Pico2025103 papers
Linha do tempo
2026Hoje · 2026🧪 1989Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

3 genes identificados com associação a esta condição. Padrão de herança: Unknown.

MAP2K1Dual specificity mitogen-activated protein kinase kinase 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Binding of extracellular ligands such as growth factors, cytokines and hormones to their cell-surface receptors activates RAS and this initiates RAF1 activation. RAF1 then further activates the dual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. Both MAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERK cascade, and catalyze the concomitant phosphorylation of

LOCALIZAÇÃO

Cytoplasm, cytoskeleton, microtubule organizing center, centrosomeCytoplasm, cytoskeleton, microtubule organizing center, spindle pole bodyCytoplasmNucleusMembrane

VIAS BIOLÓGICAS (10)
MAP2K and MAPK activationFrs2-mediated activationSignaling downstream of RAS mutantsSignaling by high-kinase activity BRAF mutantsSignaling by moderate kinase activity BRAF mutants
MECANISMO DE DOENÇA

Cardiofaciocutaneous syndrome 3

A form of cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and intellectual disability. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. Distinctive features of CFC3 include macrostomia and horizontal shape of palpebral fissures.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
99.1 TPM
Cérebro - Hemisfério cerebelar
89.3 TPM
Brain Frontal Cortex BA9
87.1 TPM
Brain Nucleus accumbens basal ganglia
71.7 TPM
Brain Anterior cingulate cortex BA24
55.9 TPM
OUTRAS DOENÇAS (5)
melorheostosiscardiofaciocutaneous syndrome 3cardiofaciocutaneous syndromeRASopathy
HGNC:6840UniProt:Q02750
BRAFSerine/threonine-protein kinase B-rafDisease-causing somatic mutation(s) inAltamente restrito
FUNÇÃO

Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway (PubMed:21441910, PubMed:29433126). Phosphorylates PFKFB2 (PubMed:36402789). May play a role in the postsynaptic responses of hippocampal neurons (PubMed:1508179)

LOCALIZAÇÃO

NucleusCytoplasmCell membrane

VIAS BIOLÓGICAS (4)
Spry regulation of FGF signalingParadoxical activation of RAF signaling by kinase inactive BRAFARMS-mediated activationSignalling to p38 via RIT and RIN
OUTRAS DOENÇAS (18)
Noonan syndrome 7LEOPARD syndrome 3melanoma, cutaneous malignant, susceptibility to, 1lung cancer
HGNC:1097UniProt:P15056
NRASGTPase NRasDisease-causing somatic mutation(s) inAltamente restrito
FUNÇÃO

Ras proteins bind GDP/GTP and possess intrinsic GTPase activity

LOCALIZAÇÃO

Cell membraneGolgi apparatus membrane

VIAS BIOLÓGICAS (2)
Signaling by moderate kinase activity BRAF mutantsNeutrophil degranulation
MECANISMO DE DOENÇA

Leukemia, juvenile myelomonocytic

An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
77.3 TPM
Fibroblastos
52.5 TPM
Skin Not Sun Exposed Suprapubic
25.1 TPM
Esôfago - Mucosa
24.4 TPM
Skin Sun Exposed Lower leg
23.4 TPM
OUTRAS DOENÇAS (13)
neurocutaneous melanocytosislarge congenital melanocytic nevusthyroid cancer, nonmedullary, 2colorectal cancer
HGNC:7989UniProt:P01111

Variantes genéticas (ClinVar)

593 variantes patogênicas registradas no ClinVar.

🧬 NRAS: NM_002524.5(NRAS):c.149C>A (p.Thr50Asn) ()
🧬 NRAS: NM_002524.5(NRAS):c.328C>T (p.Pro110Ser) ()
🧬 NRAS: NM_002524.5(NRAS):c.*3102A>G ()
🧬 NRAS: NM_002524.5(NRAS):c.503T>C (p.Met168Thr) ()
🧬 NRAS: NM_002524.5(NRAS):c.286T>C (p.Tyr96His) ()
Ver todas no ClinVar

Vias biológicas (Reactome)

51 vias biológicas associadas aos genes desta condição.

MAPK3 (ERK1) activation Frs2-mediated activation Signal transduction by L1 Uptake and function of anthrax toxins RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway MAP3K8 (TPL2)-dependent MAPK1/3 activation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by MAP2K mutants Signaling by RAF1 mutants Spry regulation of FGF signaling ARMS-mediated activation Signalling to p38 via RIT and RIN Negative regulation of MAPK pathway SHOC2 M1731 mutant abolishes MRAS complex function Gain-of-function MRAS complexes activate RAF signaling SOS-mediated signalling Activation of RAS in B cells Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signaling by SCF-KIT Signalling to RAS p38MAPK events GRB2 events in EGFR signaling SHC1 events in EGFR signaling Downstream signal transduction GRB2 events in ERBB2 signaling Tie2 Signaling EGFR Transactivation by Gastrin DAP12 signaling SHC-related events triggered by IGF1R FCERI mediated MAPK activation NCAM signaling for neurite out-growth Ras activation upon Ca2+ influx through NMDA receptor VEGFR2 mediated cell proliferation CD209 (DC-SIGN) signaling Constitutive Signaling by EGFRvIII SHC-mediated cascade:FGFR1 FRS-mediated FGFR1 signaling SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 32
2Fase 211
1Fase 12
·Pré-clínico5
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 20 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Histiocitose de células de Langerhans

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

19 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

NCT05828069 · A Study With Tovorafenib (DAY101) as a Treatment Option for …Recrutando
PHASE2
NCT06582745 · Targeted Approach to Langerhans Cell Histiocytosis (LCH) Usi…Recrutando
PHASE2
NCT04943198 · Optimization of the Time and Dosage of Vemurafenib in BRAF P…Recrutando
PHASE2
NCT04943224 · Optimization of the Time and Dosage of Trametinib in BRAF Ne…Recrutando
PHASE2
NCT04943211 · Determination of Molecular Status, the Efficacy and Safety o…Recrutando
PHASE3
NCT02402244 · Project: Every Child for Younger Patients With CancerRecrutando
NCT07431060 · Modified LCH-III Regimen With or Without Luvometinib for Mul…Recrutando
NA
NCT07371182 · Luvometinib in Pediatric SS-LCH With Special-site Single/Mul…Recrutando
NA
NCT06712810 · Q702 for the Treatment of Patients With Hematologic Malignan…Recrutando
PHASE1
NCT07187193 · Efficacy and Safety of Low-Dose Cytarabine Combined With Tha…Recrutando
PHASE2
NCT04079179 · Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH…Recrutando
PHASE2
NCT06153173 · Mirdametinib in Histiocytic DisordersRecrutando
PHASE2
NCT02670707 · Vinblastine/Prednisone Versus Single Therapy With Cytarabine…Recrutando
PHASE3
NCT07022834 · Real-world Study of Darafenib or Trametinib and Clofarabine …Recrutando
PHASE2
NCT05915208 · Histiocytic Disorder Follow-up StudyRecrutando
NCT05997602 · To Evaluate the Efficacy, Safety, and PK Characteristics of …Recrutando
PHASE2
NCT06197204 · Biomarkers for Diagnostic, Prognostic and of Response to Tre…Recrutando
NCT06078969 · Oral Prednisone in Treating LCH of Bone in Childhood and Ado…Recrutando
PHASE2
NCT06902792 · Adebrelimab Combined With Trametinib in the Treatment of Ref…Por convite
PHASE1

Outros ensaios clínicos

86 ensaios clínicos encontrados, 36 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
2.983 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 2.983

#1

Prospective Collaborative Study for Pulse Dexamethasone and Lenalidomide in Relapsed/Refractory Langerhans Cell Histiocytosis (LENDEX-LCH Study): INPHOG-HIST-19-03 (CTRI/2020/07/026937).

Pediatric blood &amp; cancer2026 Mar 15

The Indian Paediatric Haematology Oncology Group (INPHOG) multicentre study aimed to prospectively analyse the efficacy and safety of lenalidomide and dexamethasone (LENDEX) in children with refractory/relapsed Langerhans cell histiocytosis (LCH). The study was a prospective, multicentre study conducted through the INPHOG Histiocytosis Subcommittee. The Clinical Trials Registry of India registration was obtained, and the study was open to recruitment from June 2020 to June 2023. A total of 15 children were included from seven centres in India, median age being 4 years (Range 3-13 years). Thirteen children were diagnosed to have multisystem disease at relapse with involvement of skin, bone and liver; and one child each with multifocal bone disease and single site bone lesion. One child with refractory lung disease had progression after two cycles of LENDEX and was taken off protocol. Four (26%) children achieved CR after six cycles of LENDEX; while eight (53%) children had PR at three and six cycles, with CR at the end of nine cycles of LENDEX. The combination was well tolerated, the most common adverse effects being mild anaemia and myalgia. There were no deaths within the cohort, with a median follow-up of 24 months (Range 18-48 months). The overall response rate was 73%, with 26% responses at six cycles and 53% at nine cycles of LENDEX. LENDEX is well tolerated and effective in 73% children with relapsed/refractory LCH. Future studies would include nine cycles of LENDEX followed by maintenance for 12 months with 6-mercaptopurine.

#2

Trametinib Monotherapy in the Treatment of Pediatric Refractory/Relapse Langerhans Cell Histiocytosis.

Pediatric blood &amp; cancer2026 Mar 13

Standardized salvage treatments for refractory/relapse Langerhans cell histiocytosis (LCH) remain to be established. Trametinib (TRA) has shown marked efficacy in LCH, but cohort studies regarding efficacy and safety of TRA monotherapy in refractory/relapse LCH were scarce. We retrospectively analyzed 22 patients with refractory/relapse LCH treated with TRA monotherapy. Patients were treated for a median of 21.4 months (3.0-51.6 months). Nineteen (86.4%) of 22 of patients remained progression-free during TRA treatment. Sixteen patients stopped TRA (not due to progression or toxicity), of which 10 remained progression free, with median follow-up time of 28.7 months (1.5-44.6 months) after TRA withdrawal, and 6 patients experienced relapse, with median time to relapse from post-TRA withdrawal of 3.7 months (2.7-16.5 months). Two patients continued on TRA at last follow-up and one switched to chemotherapy due to toxicity. Three-year event-free survival was 50.7% (95% CI: 27.7-69.8), with a median follow-up time of 36.4 months (3.0-67.6 months). From TRA initiation to 12 months of treatment, cell-free BRAF/MAP2K1 mutation status in blood presented as negative to negative or positive to negative was correlated with superior event-free survival rate (EFS) rate. Toxicity was tolerable, and adverse events were predominantly skin rash (77.3%), paronychia (22.7%), and diarrhea (13.6%). Overall, TRA was effective and safe in the treatment of patients with refractory/relapse LCH, offering a convenient therapeutic alternative.

#3

Isolated Intracranial Rosai-Dorfman Disease Mimicking Sellar Pituitary Adenoma: a case report and literature review.

BMC neurology2026 Mar 02

Rosai-Dorfman disease (RDD), also known as sinus histiocytosis with massive lymphadenopathy (SHML), is an extremely rare non-Langerhans cell histiocytosis. The diagnostic histiocytes in RDD are characterized by the immunophenotypic markers S100 (+), CD68 (+), and CD1a (-) (Abla O, Blood 131: 2877, 2018),(Emile JF, Blood 127: 2672, 2016) , and exhibit phagocytosis with varying frequency. To our knowledge, this is the first reported case of isolated Intracranial Rosai-Dorfman Disease Mimicking Sellar Pituitary Adenoma, with peripheral facial paralysis as the initial presentation. By integrating imaging findings, histopathological features, and treatment response, we explore the diagnostic challenges and management strategies, aiming to enhance clinicians' awareness of RDD involving the pituitary. We report the case of a 50-year-old Han Chinese female who presented with left-side peripheral facial paralysis and tender enlargement of the left cervical lymph nodes. Pituitary MRI revealed an intrasellar mass with homogeneous enhancement, initially diagnosed as a pituitary adenoma. The patient underwent transnasal transsphenoidal endoscopic resection of the pituitary adenoma. But histopathology and immunohistochemistry (S100+, CD68+, CD1a-) confirmed the diagnosis of RDD. Postoperatively, the facial paralysis improved, Unfortunately, 6 months follow-up MRI showed tumor recurrence. The clinical manifestations of intrasellar RDD are insidious and lack specificity, making it easy to confuse with common pituitary space-occupying lesions. Currently, surgical resection remains the gold standard for definitive diagnosis and is the primary therapeutic intervention, long-term follow-up is crucial for monitoring recurrence.

#4

Behavioral and emotional problems and quality of life in Chinese children with Langerhans cell histiocytosis.

BMC pediatrics2026 Feb 27

This study intended to explore behavioral and emotional problems and quality of life, as well as their related factors in Chinese children with Langerhans cell histiocytosis (LCH). This was a cross-sectional study. Subjects were included from April 2023 to September 2023. Child behavior checklist (CBCL), pediatric quality of life inventory™ version 4.0 (PedsQLTM4.0), and version 3.0 (PedsQLTM3.0) Cancer Module were used to assess behavioral and emotional problems and quality of life. A total of 120 children with LCH were included. Twenty-six (21.7%) children had behavioral and emotional problems. Age at diagnosis ≥ 4 years [odds ratio (OR) = 0.344, P = 0.022] and major caregiver with an educational level of junior college and above (OR = 0.314, P = 0.035) were independently associated with a lower possibility of achieving CBCL total problem score ≥ 35. Electronic product usage time ≥ 2 h per day (B=-6.024, P = 0.011) and caesarean section (B=-6.006, P = 0.012) were independently related to a lower total PedsQLTM4.0 score, while age at diagnosis ≥ 4 years (B = 9.183, P = 0.004) showed an inverse trend. Second-line treatment was independently related to a lower total PedsQLTM3.0 Cancer Module score (B=-5.578, P = 0.021). In this study, 21.7% of Chinese children with LCH exhibit behavioral and emotional problems. Age at diagnosis < 4 years, major caregiver with an educational level of high school and below, electronic product usage time ≥ 2 h, caesarean section, and second-line treatment are related to behavioral and emotional problems and impaired quality of life in Chinese children with LCH. Not applicable.

#5

Choriocarcinoma presenting with cystic lung metastasis mimicking diffuse cystic lung disease.

BMJ case reports2026 Feb 25

Choriocarcinoma is a highly aggressive malignant germ cell tumour containing syncytiotrophoblasts that secrete beta-human chorionic gonadotropin, and it has a poor prognosis, with a dismal 5-year survival rate of <5%. It generally affects young individuals. Cystic lesions in the lung are uncommon in malignancies that can predispose patients to spontaneous pneumothorax. Multiple cystic lesions are less commonly seen in metastatic disease. Diffuse cystic lung diseases (DCLD) are a group of diseases characterised by cysts in the bilateral lung fields that are not necessarily evenly distributed. The differential diagnosis is limited and typically includes lymphangioleiomyomatosis and pulmonary Langerhans cell histiocytosis. Sometimes, metastatic malignancy can present as DCLD. Metastatic leiomyoma, endometrial stromal sarcoma and cellular fibrous histiocytic tumours have been reported as causes of lung cysts. We report a case of choriocarcinoma with cystic lung metastasis in a woman in her 30s.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC3.985 artigos no totalmostrando 196

2026

Orbital Langerhans Cell Histiocytosis in Young Pediatric Patients: Two Case Reports and Literature Review.

Pediatric health, medicine and therapeutics
2026

Frontotemporal-orbitozygomatic approach for pediatric cranio-orbital tumors: a single-center experience.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
2026

Liver Histiocytosis Masquerading as Hepatic Dysfunction: Rare Case Story.

Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki)
2026

Case Report: A 69-year-old woman with dermatopathic lymphadenopathy and hypercalcemia after COVID-19 infection.

Frontiers in immunology
2026

Facial Cutaneous Rosai-Dorfman Disease Misdiagnosed as Sporotrichosis: A Case Report and Literature Review.

Clinical, cosmetic and investigational dermatology
2026

Case Report: Complete remission of refractory Langerhans cell sarcoma following CLAG-M chemotherapy and allogeneic hematopoietic stem cell transplant.

Frontiers in oncology
2026

Diffuse red-brown papules in a toddler.

JAAD case reports
2026

Cutaneous-to-Bronchial Rosai-Dorfman Disease without Lymphadenopathy: A Rare Case Report and Literature Review.

Clinical, cosmetic and investigational dermatology
2026

Use of cryobiopsy for diagnosis and treatment of a rare laryngeal tumor in pediatrics.

Archivos argentinos de pediatria
2026

Erdheim-Chester Disease: A Diagnostic Challenge.

Cureus
2026

Case Report: A rare adult multisystem Langerhans cell histiocytosis involving the skin, thyroid, jaw-periodontal region, and bone: diagnostic challenges and complementary PET/CT-SPECT/CT findings.

Frontiers in oncology
2026

Successful Treatment of Histiocytic Sarcoma in Childhood.

Cureus
2026

Prospective Collaborative Study for Pulse Dexamethasone and Lenalidomide in Relapsed/Refractory Langerhans Cell Histiocytosis (LENDEX-LCH Study): INPHOG-HIST-19-03 (CTRI/2020/07/026937).

Pediatric blood &amp; cancer
2026

The utility of PU.1 immunohistochemical marker in differentiating granular cell tumor from oral histiocytic lesions.

Oral surgery, oral medicine, oral pathology and oral radiology
2026

Trametinib Monotherapy in the Treatment of Pediatric Refractory/Relapse Langerhans Cell Histiocytosis.

Pediatric blood &amp; cancer
2026

Evolving Pathological Stages of Severe Pulmonary Langerhans Cell Histiocytosis: Clinical Insights From a Case Involving an Infant.

Pediatric blood &amp; cancer
2026

[Adult thoracic Langerhans cell histiocytosis:a case report].

Zhongguo gu shang = China journal of orthopaedics and traumatology
2026

Prognostic factors and clinical outcomes in pediatric Langerhans Cell Histiocytosis: a retrospective cohort study on event-free survival.

Hematology (Amsterdam, Netherlands)
2026

Skin-limited Langerhans cell histiocytosis in an adult.

Dermatology reports
2026

Cutaneous Rosai-Dorfman disease: a case report of disease limited only to skin.

Dermatology reports
2026

A refractory polyarthritis revealing a multicentric reticulohistiocytosis.

Modern rheumatology case reports
2026

Fine-Needle Aspiration as a Key Diagnostic Tool in Pediatric Rosai-Dorfman Disease: A Case Report of a 12-Year-Old Male.

International medical case reports journal
2026

Isolated Intracranial Rosai-Dorfman Disease Mimicking Sellar Pituitary Adenoma: a case report and literature review.

BMC neurology
2026

What to do to beat Langerhans cell histiocytosis of bone? A narrative review and case series of radiofrequency ablation.

EFORT open reviews
2026

Pheochromocytoma With Langerhans Cell Histiocytosis: A Rare Tumor-in-Tumor Case.

Clinical case reports
2026

Clinicopathological features of gastric Langerhans cell histiocytosis and a literature review.

Journal of clinical and experimental hematopathology : JCEH
2026

Behavioral and emotional problems and quality of life in Chinese children with Langerhans cell histiocytosis.

BMC pediatrics
2026

Origin, diagnosis and treatment of periocular Histiocytic disorders- state-of-the-art review.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
2026

CD71 expression in Rosai-Dorfman disease: a useful adjunct marker in the differential diagnosis of histiocytic proliferations.

Histopathology
2026

Cystic lung diseases in the daily routine: a comprehensive step-wise algorithm for the radiological diagnosis of cystic lung lesions and diffuse cystic lung diseases.

RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin
2026

Choriocarcinoma presenting with cystic lung metastasis mimicking diffuse cystic lung disease.

BMJ case reports
2026

Otolaryngological Manifestations of Paediatric Langerhans Cell Histiocytosis: A Systematic Literature Review and Statewide Case Series.

The Journal of laryngology and otology
2026

Tufted hair folliculitis as an unusual cutaneous manifestation of systemic Langerhans cell histiocytosis.

Italian journal of dermatology and venereology
2026

Cervical vertebra plana secondary to Ewing sarcoma: A case report.

Radiology case reports
2026

A Systematic Review of Erdheim-Chester Disease and IgG4-Related Disease: Building a Diagnostic Framework for the Rheumatologist.

Journal of clinical rheumatology : practical reports on rheumatic &amp; musculoskeletal diseases
2026

Blood MMP-7 and TNF-α levels as potential prognostic biomarkers for adult pulmonary Langerhans cell histiocytosis.

Scientific reports
2025

Case Report: A concomitant case of eosinophilic granuloma of the spine and Fasciola hepatica infection of the liver in a young patient, and review of the literature.

Frontiers in surgery
2026

MACOP-B in Adult Langerhans Cell Histiocytosis Confirms Durable Organ Responses at an Updated Long-Term Follow-Up.

American journal of hematology
2026

Perioperative multidisciplinary rescue of a patient with Erdheim - Chester disease and multi-system involvement: a case report.

Frontiers in medicine
2026

Isolated gastrointestinal Langerhans cell histiocytosis in a 16-month-old child: A case report.

JPGN reports
2026

Management of a Pediatric Patient With Langerhans Cell Histiocytosis Using General Anesthesia.

Cureus
2026

Recurrent vulvar ulcers led to the multidisciplinary management of a rare vulvar condition, Langerhans cell histiocytosis.

JAAD case reports
2026

Alopecia as an atypical presentation of Langerhans cell histiocytosis in an adult male.

JAAD case reports
2026

Red-brown and purpuric eroded papules and patches in the intertriginous regions.

JAAD case reports
2026

Long-term MAPK inhibition of childhood refractory-Langerhans cell histiocytosis: an observational study on 288 patients.

Blood advances
2026

[Guideline for the diagnosis and treatment of Langerhans cell histiocytosis in children (2026)].

Zhonghua er ke za zhi = Chinese journal of pediatrics
2026

A Case of Multisystem Langerhans Cell Histiocytosis with Palmar Hyperkeratosis and Purpuric Nail Bands as the Initial Presentation: New Insights into An Old Disease.

Indian dermatology online journal
2026

[Special aspects of magnetic resonance imaging of pediatric bone marrow].

Radiologie (Heidelberg, Germany)
2026

An Adult Case of Chest Wall Langerhans Cell Histiocytosis Mimicking Malignancy and Responding to Targeted Therapy.

Cureus
2026

Neurodegeneration in Langerhans Cell Histiocytosis: beyond a Sequela.

Anales de pediatria
2026

Incidental Diagnosis of Erdheim-Chester Disease in a 42-Year-Old Man With Persistent Elevated ESR and Peri-Ocular Xanthomas: A Case Report.

Clinical case reports
2026

Uncommon presentation of hepatic Langerhans cell histiocytosis in a young adult: a diagnostic challenge.

BMJ case reports
2026

Predictive value of metabolic parameters from PET/CT in adult multifocal Langerhans cell histiocytosis.

Annals of nuclear medicine
2026

Sotatercept in Pulmonary Langerhans Cell Histiocytosis-Associated Pulmonary Hypertension: A Case Series and Systematic Review.

Pulmonary circulation
2026

Efficacy and safety of cladribine in adult pulmonary langerhans cell histiocytosis: a phase II study.

The European respiratory journal
2026

Erdheim-Chester disease presenting with multisystem involvement: A case report.

World journal of clinical cases
2025

Asymmetric adult-onset asthma with periocular xanthogranuloma (AAPOX) associated with IgG4-related disease: a case report.

Frontiers in surgery
2026

Corrigendum to "Langerhans cell histiocytosis of the spine in adults: A rare and controversial disorder: A systematic review" [Clin. Neurol. Neurosurg. 255 (2025) 108991].

Clinical neurology and neurosurgery
2026

Non-Traumatic Clavicular Lesions in Children: Case Series and Literature Review.

Children (Basel, Switzerland)
2026

Langerhans Cell Histiocytosis Presenting With Diabetes Insipidus in a 2 Years Old Child: A Case Report.

Clinical case reports
2026

Descriptive analysis of primary intermediate and benign spine tumors: A retrospective study using the Bone and Soft Tissue Tumor Registry in Japan.

Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
2026

Delayed Neurologic Response to Dabrafenib and Trametinib in the Case of Mixed Histiocytosis (LCH/ECD): Case Report and Literature Review.

Reports (MDPI)
2026

Hearing loss in Langerhans cell histiocytosis: close association with central nervous system consequences.

International journal of hematology
2025

Paediatric Langerhans Cell Histiocytosis: A 20-Year Single-Centre Retrospective Study of 35 Cases.

Cureus
2026

A case of Langerhans cell histiocytosis localized in the temporal bone, which presented as sudden sensorineural hearing loss: A case report and review of the literature.

SAGE open medical case reports
2026

Survival outcomes and adverse prognostic factors of Langerhans cell histiocytosis: a 40-year experience from a single tertiary center in Thailand.

Annals of hematology
2026

Adult-onset intratracheal xanthogranuloma presented with uncontrolled asthma.

BMJ case reports
2026

Primary pulmonary Langerhans cell histiocytosis: comprehensive clinicopathologic and molecular genetic analysis of 13 cases.

Human pathology
2026

[Histiocytosis X discovered after chemotherapy treatment for mesothelioma].

Revue medicale de Liege
2026

Current Approaches and Therapeutic Strategies for Hypothalamic Syndrome in Patients with Childhood-onset Craniopharyngioma.

Journal of clinical research in pediatric endocrinology
2026

Radiologic Approach to Cystic Lung Diseases: From Cyst Definition to Diagnosis.

Seminars in roentgenology
2026

Prognostic factor analysis of oral and maxillofacial Langerhans cell histiocytosis based on clinical findings and tumour microenvironment.

BMC oral health
2026

Interstitial Lung Diseases Presenting as Small Nodules: Imaging Phenotypes.

Seminars in roentgenology
2025

[Clinical Efficacy Analysis of 38 Pediatric Cases of Recurrent and Refractory Langerhans Cell Histiocytosis].

Zhongguo shi yan xue ye xue za zhi
2026

Nanoparticle-enhanced cytology: a 2025 breakthrough for rapid diagnosis of Erdheim-Chester disease.

Annals of medicine and surgery (2012)
2026

The use of MEK inhibitors in pediatric patients presenting with respiratory distress and laryngeal Rosai-Dorfman Disease: Two case reports.

International journal of pediatric otorhinolaryngology
2025

[Etiological evaluation of pericardial effusion: A case report of adult ECD-LCH overlap syndrome].

Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
2026

From a Long-Standing Yellowish Plaque to a Diagnosis of a Rare Disorder: A Case of Erdheim-Chester Disease Treated With Vemurafenib.

American journal of medical genetics. Part A
2026

Oral-Onset Langerhans Cell Histiocytosis in a Noncompliant Adult: A Cautionary Case of Multisystem Progression.

Australian dental journal
2025

Cytological Findings in Pediatric Thoracic Tumors: A Review of Diagnostic Insights and Pitfalls.

Acta cytologica
2025

Langerhans cell histiocytosis manifesting at birth: a neonatal case with BRAF V600E mutation.

Diagnostic pathology
2025

Multisystem Langerhans cell Histiocytosis presenting with spontaneous pneumothorax in a toddler: case report and literature review.

Oxford medical case reports
2026

Postoperative Radiotherapy in Spinal Rosai-Dorfman Disease: A Case Report and Literature Review.

Case reports in oncology
2025

Stereotactic radiosurgery for intracranial Langerhans cell histiocytosis: A multi-institutional case series with long-term follow-up.

Brain &amp; spine
2026

Repurposing osteoporosis medications for other diseases: a narrative review by the European Calcified Tissue Society (ECTS).

Bone
2026

Rethinking "asthma" in adult-onset "asthma" with periocular xanthogranuloma.

JAAD case reports
2026

Hepatitis B Reactivation in Children During Chemotherapy for Hematologic Malignancies: Experience of 24 Cases Including Long-term Follow-up.

Journal of clinical and experimental hepatology
2025

At the crossroads of infection and malignancy: the challenge of tuberculosis in migrating populations - Case Report and Epidemiologic Analysis.

BMC infectious diseases
2026

Combination Therapy With Dabrafenib and Trametinib for Langerhans Cell Histiocytosis-Associated Neurodegenerative Disease.

Pediatric blood &amp; cancer
2026

CHOROIDAL INFILTRATION IN ERDHEIM-CHESTER DISEASE: A CASE SERIES.

Retinal cases &amp; brief reports
2025

Treating metastatic extraocular retinoblastoma complicated with Langerhans cell histiocytosis.

GMS ophthalmology cases
2025

Case Report: Systematic endoscopic characterization of synchronous esophageal, gastric, and colorectal involvement in multisystem Langerhans cell histiocytosis.

Frontiers in medicine
2025

P21 A rare case of eosinophilic pustular folliculitis presenting with pustules and bullae at birth.

The British journal of dermatology
2025

A 26-year-old with persistent cough of unclear origin.

Breathe (Sheffield, England)
2026

Efficacy, safety, and relapse outcomes of MAPK inhibitors in pediatric Langerhans cell histiocytosis: A real-world study.

International journal of cancer
2025

Adult onset multisystem Langerhans cell histiocytosis initially presenting with arginine vasopressin deficiency: a case report.

Frontiers in medicine
2025

Bilateral temporal skull xanthoma characterized as a Langerhans cell histiocytosis: a case report.

Journal of medical case reports
2026

Rosai-Dorfman Disease Involving Thymus and Aorta Revealed by 18 F-FDG PET/CT.

Clinical nuclear medicine
2025

Perianal Langerhans cell hyperplasia characterized by perianal ulcerative lesions after hemorrhoid surgery: A case report.

Medicine
2025

An endocrinological point of view on a large series of pituitary stalk lesions.

Pituitary
2026

"Multifocal, intra-axial Langerhans cell histiocytosis presenting with central diabetes insipidus in teenage pregnancy: A case report".

Radiology case reports
2025

Juvenile Xanthogranuloma: A Visual Clinical Diagnosis.

Cureus
2025

[Current Imaging Approaches for Pediatric Brain Tumors].

No shinkei geka. Neurological surgery
2025

Gastric Bloom: Flower-like Lesions of Isolated Gastrointestinal Langerhans Cell Histiocytosis.

ACG case reports journal
2025

Bilateral maxillary and mandibular involvement of Langerhans cell histiocytosis: A rare case report.

Journal of Indian Society of Periodontology
2025

Advances in the diagnosis and management of pediatric Langerhans cell histiocytosis and Rosai-Dorfman disease: therapies, biomarkers, and response assessment.

Hematology. American Society of Hematology. Education Program
2025

[Langerhans cell histiocytosis diagnosed in mediastinal lymph nodes by endoscopic ultrasound-guided fine-needle aspiration].

Anales del sistema sanitario de Navarra
2025

miRNAs in Erdheim-Chester Disease: A Paradigm of Multisystem Histiocytosis.

The journal of gene medicine
2026

The Nutritional Impact of Childhood Cancer: Insights from a Feasibility Cohort Study.

Nutrition and cancer
2025

Tumoral Stage of Mycosis Fungoides, Misdiagnosed With Wells Syndrome and Langerhans Cell Histiocytosis Histologically: A Challenging Case and Review of the Literature.

Cancer reports (Hoboken, N.J.)
2025

Thoracic eosinophilic granuloma in a 23-month-old child: a rare case and literature review.

European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
2025

Neurodegenerative Langerhans cell histiocytosis: long-term follow-up of 63 patients from the Italian Registry.

Haematologica
2025

Cell-free BRAF-V600E levels predict progression-free survival in children with Langerhans cell histiocytosis treated with dabrafenib and maintenance chemotherapy.

Haematologica
2025

Hepatic Involvement as the Initial Manifestation of Adult Langerhans Cell Histiocytosis.

ACG case reports journal
2025

Mixed Erdheim-Chester disease with thoraco-abdominal involvement.

Acta radiologica open
2026

Patient and Caregiver Perspectives on Clinical Care, Comprehensive Support, and Communication in Langerhans Cell Histiocytosis Management.

Pediatric blood &amp; cancer
2025

Systemic Langerhans Cell Histiocytosis Revealed by Atypical Vulvar Lesions in a Child.

Journal of pediatric and adolescent gynecology
2025

Solitary Congenital Self-Healing Langerhans Cell Histiocytosis.

Journal of cutaneous medicine and surgery
2025

Chronic myelomonocytic leukaemia occurring in patients with pulmonary Langerhans cell histiocytosis: A common progenitor?

Respiratory medicine and research
2026

Clinicopathological features of hepatic Langerhans cell histiocytosis: report of ten cases and review of the literature.

Annals of diagnostic pathology
2025

Gastric Langerhans Cell Histiocytosis is Easily Ignored or Misdiagnosed in Stomach Biopsy and Indicates a Poor Outcome in Multisystem Langerhans Cell Histiocytosis.

International journal of surgical pathology
2025

Incidental Renal Langerhans Cell Histiocytosis Within Clear Cell Renal Carcinoma: A Case Report and Literature Review.

Case reports in urology
2025

[Exploring Langerhans cell histiocytosis in childhood: case series].

Boletin medico del Hospital Infantil de Mexico
2025

See it sooner: The role of point-of-care ultrasound in detecting malignant and invasive lesions presenting to the paediatric emergency department - A pictorial review.

Ultrasound (Leeds, England)
2025

Long-term follow-up of a case of Langerhans cell histiocytosis of the cervical spine with pulmonary involvement.

Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
2025

Langerhans Cell Histiocytosis and Mastocytosis: A Rare Association.

Dermatology practical &amp; conceptual
2025

Intra-arterial melphalan for treatment of neurologic histiocytic neoplasms.

Journal of the neurological sciences
2026

Real-world outcomes in adult histiocytosis: the uncharted territory of orphan diseases.

Leukemia &amp; lymphoma
2026

Oral and Craniofacial Development and Immunology.

Advances in experimental medicine and biology
2025

[A case of diffuse cystic lung disease with severe pulmonary hypertension in a reproductive-aged female].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
2025

Erdheim-Chester Disease Mimicking a Malignant Pituitary Stalk Tumor With Ventricular Dissemination: A Case Report.

Brain tumor research and treatment
2025

Efficacy and safety of dabrafenib-targeted therapy for pediatric langerhans cell histiocytosis: a systematic review and meta-analysis.

Translational pediatrics
2025

Concavities of the margins of focal bone lesions on MRI: a retrospective study of 586 cases.

Insights into imaging
2025

Tonsillar langerhans cell sarcoma with gastrointestinal metastasis: a rare case report.

AME case reports
2025

Distinct Presentations of Langerhans Cell Histiocytosis in Children: A Case Series.

Case reports in oncological medicine
2025

Erdheim-Chester disease: A multisystem non-Langerhans cell histiocytosis with cutaneous involvement.

The journal of the Royal College of Physicians of Edinburgh
2025

Application of pretreatment 18F-FDG PET metabolic parameters in children with Langerhans cell histiocytosis.

Annals of hematology
2025

Rosai-Dorfman disease presenting without systemic symptoms in childhood.

BMJ case reports
2025

Malignancy-associated Multicentric Reticulohistocytosis Mimicking Dermatomyositis-like Features, with a Significant Ultrasound Finding.

Internal medicine (Tokyo, Japan)
2025

Delayed diagnosis of pituitary LCH with BRAFV600E mutation: A case report and literature review.

Medicine
2025

Histiocyte Society blueprint for non-Langerhans cell histiocytosis research: unraveling complex diseases through collaboration.

Haematologica
2025

Histiocyte Society blueprint for Langerhans cell histiocytosis research: from cell-of-origin to a more comprehensive cure.

Haematologica
2025

Peripheral immune indicators and their predictive value in disease progression or relapse of pediatric Langerhans cell histiocytosis.

Jornal de pediatria
2025

A retrospective diagnosis of trauma-related self-resolving hemorrhagic skull lesions of Langerhans cell histiocytosis in a child through cytopathologic re-evaluation of a prior post-traumatic parotid gland hematoma.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
2026

Langerhans Cell Histiocytosis in Cardiofaciocutaneous Syndrome.

American journal of medical genetics. Part A
2026

Bile Duct Targeting or Preservation: Contrasting Liver Histology in Langerhans Cell Histiocytosis and Disseminated Juvenile Xanthogranuloma.

Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
2025

The Impact of Hybrid Therapy on Langerhans Cell Histiocytosis of the Mandible in an Older Male: A Case Report and Literature Review.

Case reports in otolaryngology
2025

Rosai-Dorfman Disease of the Breast: Radiologic-Pathologic Correlation.

Journal of breast imaging
2025

Treatment of cutaneous Langerhans cell histiocytosis with ruxolitinib 1.5% cream.

JAAD case reports
2025

Congenital self-healing Langerhans cell histiocytosis vs benign cephalic histiocytosis: A comprehensive literature review of pediatric cutaneous histiocytoses.

JAAD case reports
2025

Effective vemurafenib monotherapy for refractory Langerhans cell histiocytosis with sustained results post-withdrawal for over two years: a case report.

Frontiers in oncology
2025

Beyond Hepatitis: A Rare Case of Multisystem Langerhans Cell Histiocytosis in a Child.

Clinical case reports
2026

RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition.

Cancer cell
2025

Ear Discharge and Destructive Postauricular Mass: An ENT Manifestation of Langerhans Cell Histiocytosis.

British journal of hospital medicine (London, England : 2005)
2025

Health-Related Quality of Life and Social Outcomes in Adolescents and Young Adult Survivors of Childhood Cancer: A Single-Center Case-Control Study from Crete, Greece.

Reports (MDPI)
2025

Sinus and palatal Rosai-Dorfman Disease: Case report and review of the literature.

American journal of otolaryngology
2025

Primary Langerhans Cell Histiocytosis Associated With Multiple Lymphoepithelial Cysts: A Challenging Case.

Pathology international
2025

The etiological diagnosis of "Primary" hypophysitis requires prolonged follow-up: A case of Langerhans cell histiocytosis.

Annales d'endocrinologie
2025

Pulmonary Langerhans Cell Histiocytosis.

Clinics in chest medicine
2025

Teaching NeuroImage: Isolated Hypothalamic Langerhans Cell Histiocytosis.

Neurology
2025

Necrobiotic xanthogranuloma of larynx - an extremely rare case report.

Logopedics, phoniatrics, vocology
2026

Safety and feasibility of duct-to-duct biliary anastomosis in pediatric liver transplantation: A single-center retrospective study.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
2025

Erdheim-Chester Disease Masquerading as Leukemia: Outwitting the Need for Transplant.

Cureus
2025

Langerhans cell histiocytosis presenting as aggressive periodontitis to a paediatric dentist.

BMJ case reports
2026

Solitary eyelid xanthogranuloma in an immunocompetent young adult: diagnostic challenges and insights.

Orbit (Amsterdam, Netherlands)
2025

A Missed Case of Langerhans Cell Histiocytosis of the Proximal Femur after Total Hip Arthroplasty in an Adult: A Case Report.

Journal of orthopaedic case reports
2025

Pediatric nummular headache: review of the literature and a case series with nosographic considerations.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2025

Agminated, Eruptive Nevi in Patients With a History of Langerhans Cell Histiocytosis.

Pediatric dermatology
2025

Sustained Response to Pan-BRAF Inhibitor Plixorafenib (FORE8394, PLX8394) in a Young Adult With Neurodegenerative Langerhans Cell Histiocytosis.

JCO precision oncology
2025

Langerhans Cell Histiocytosis Successfully Treated with Combination of Thalidomide and Corticosteroid.

European journal of case reports in internal medicine
2025

Cutaneous Rosai-Dorfman Disease After COVID-19 Vaccination: Rare Occurrence with Challenging Presentation.

Seminars in musculoskeletal radiology
2025

Langerhans Cell Histiocytosis Mimicking Spinal Tuberculosis.

Mayo Clinic proceedings
2025

Congenital solitary neck ulcer as a presentation of Langerhans cell histiocytosis.

Skin health and disease
2025

Luvometinib in patients with Langerhans cell histiocytosis, Erdheim-Chester disease, and other histiocytic neoplasms: a single-arm, multicentre, phase 2 study.

EClinicalMedicine
2025

Long-Standing Bilateral Adult-Onset Orbital Xanthogranuloma With Unique Histologic Findings Uncovering the Diagnosis of Sitosterolemia.

The American Journal of dermatopathology
2025

Bilateral Spontaneous Pneumothorax in a Young Gentleman.

Respirology case reports
2025

Juvenile xanthogranuloma as a potential early manifestation of neurofibromatosis type 1: A case report.

Medicine
2025

[Langerhans Cell Histiocytosis in Children and Adults - An Interdisciplinary Diagnostic and Therapeutic Challenge].

Deutsche medizinische Wochenschrift (1946)
2025

Patients with langerhans cell histiocytosis and hypothalamic-pituitary involvement: insights from the HEROS study cohort.

Pituitary
2025

Reactive Histiocytic Proliferation in Rheumatoid Arthritis Mimicking Erdheim-Chester Disease.

Cureus
2025

Clofarabine monotherapy in refractory multisystem LCH with gastrointestinal involvement.

Pediatric hematology and oncology
2025

Low Bone Mass in Probable CD1a-negative Langerhans Cell Histiocytosis: A Diagnostic Challenge.

JCEM case reports
2025

A rare case of Langerhans cell histiocytosis with unexplained endocrine dysfunction and extensive skeletal involvement in a Pediatric patient.

Oxford medical case reports
2025

Diagnosis and treatment of Langerhans cell histiocytosis in adults.

Innovation (Cambridge (Mass.))
2025

A Case of Extra-nodal Rosai-Dorfman Disease.

Cureus
2025

Langerhans cell histiocytosis with mesenteric involvement successfully treated with trametinib: a rare cause of small intestine obstruction.

International journal of hematology
2025

Langerhans Cell Histiocytosis in the central nervous system, cranial and spinal bones: imaging features.

Expert review of clinical immunology
2025

A clinical study incorporating multimodal 18F-FDG PET/CT metabolic parameters, genetic markers, and clinical characteristics for the evaluation and prediction of treatment efficacy and prognosis in Langerhans cell histiocytosis.

Frontiers in medicine
2025

Understanding cystic lung lesions in smokers with interstitial lung disease: radiologic-pathological correlation.

Insights into imaging
2026

Refractory multisystem Langerhans cell histiocytosis in an infant: use of vemurafenib as a therapeutic option.

Archivos argentinos de pediatria
2025

Periodontal Manifestations of Systemic Diseases.

Journal of periodontal research
2025

Unraveling the diagnosis of rare genetic disorder - Langerhans cell histiocytosis.

Journal of Indian Society of Periodontology
2025

Transorbital Endoscopic Approach to the Orbital Apex Via the Superior Lid Crease: A Clinical Series.

Ophthalmic plastic and reconstructive surgery
2025

18F FDG PET/CT in a Rare Case of Erdheim-Chester Disease with Extensive Cutaneous and Skeletal Involvement.

Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India
2025

Expression and clinical correlation of cathepsin S, programmed cell death-1 ligand 1, and BRAFV600E mutation in children with Langerhans cell histiocytosis.

The Turkish journal of pediatrics
2025

Whole-body MRI in Pediatric Langerhans Cell Histiocytosis-A Comparison With FDG-PET/CT.

Journal of pediatric hematology/oncology
Ver todos os 3.985 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Histiocitose de células de Langerhans.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Histiocitose de células de Langerhans

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Prospective Collaborative Study for Pulse Dexamethasone and Lenalidomide in Relapsed/Refractory Langerhans Cell Histiocytosis (LENDEX-LCH Study): INPHOG-HIST-19-03 (CTRI/2020/07/026937).
    Pediatric blood &amp; cancer· 2026· PMID 41834326mais citado
  2. Trametinib Monotherapy in the Treatment of Pediatric Refractory/Relapse Langerhans Cell Histiocytosis.
    Pediatric blood &amp; cancer· 2026· PMID 41823178mais citado
  3. Isolated Intracranial Rosai-Dorfman Disease Mimicking Sellar Pituitary Adenoma: a case report and literature review.
    BMC neurology· 2026· PMID 41772466mais citado
  4. Behavioral and emotional problems and quality of life in Chinese children with Langerhans cell histiocytosis.
    BMC pediatrics· 2026· PMID 41761152mais citado
  5. Choriocarcinoma presenting with cystic lung metastasis mimicking diffuse cystic lung disease.
    BMJ case reports· 2026· PMID 41741123mais citado
  6. B-Acute Lymphoblastic Leukemia Masquerading as Multifocal Langerhans Cell Histiocytosis: a Diagnostic Paradigm Shift.
    Clin Lab· 2026· PMID 41979620recente
  7. Cutaneous Rosai-Dorfman Disease Misdiagnosed as Granulomatous Dermatitis: A Diagnostic Pitfall.
    Cureus· 2026· PMID 41978607recente
  8. Age-Stratified Imaging Selection in Langerhans Cell Histiocytosis: Towards a Clinical Decision Framework.
    J Clin Med· 2026· PMID 41976879recente
  9. Spontaneous regression of a presumed orbitocranial eosinophilic granuloma in an adult patient: illustrative case.
    J Neurosurg Case Lessons· 2026· PMID 41974063recente
  10. Immunohistochemistry-Based Screening for Targetable Kinase Alterations in Non-Langerhans Cell Histiocytosis with Juvenile Xanthogranuloma morphology.
    Virchows Arch· 2026· PMID 41968182recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:389(Orphanet)
  2. OMIM OMIM:604856(OMIM)
  3. MONDO:0018310(MONDO)
  4. GARD:6858(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Artigo Wikipedia(Wikipedia)
  8. Q374036(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Histiocitose de células de Langerhans
Compêndio · Raras BR

Histiocitose de células de Langerhans

ORPHA:389 · MONDO:0018310
Prevalência
1-9 / 100 000
Herança
Unknown
CID-10
C96.0 · Doença de Letterer-Siwe
CID-11
Ensaios
36 ativos
Início
All ages
Prevalência
1.5 (Europe)
MedGen
UMLS
C0019621
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades